Michel M. Robert's most recent trade in Bio-Key International Inc. was a trade of 5,000 Common Stock done . Disclosure was reported to the exchange on May 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 5,000 | 22,303 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.79 per share. | 27 May 2025 | 1,266 | 23,569 (0%) | 0% | 0.8 | 1,000 | Common Stock |
| Verastem Inc | Michelle J. Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michelle J. Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 8,333 | 16,666 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 3,897 | 17,303 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 2,971 | 13,406 (0%) | 0% | 0 | Common Stock | |
| Daxor Corp. | Robert J. Michel | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 10 Mar 2025 | 1,000 | 17,050 (0%) | 0% | 8 | 8,000 | Daxor Common Stock |
| Geron Corp. | Michelle Robertson J. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 656,000 | 656,000 | - | - | Stock Option (right to buy) | |
| Geron Corp. | Michelle Robertson J. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 110,000 | 110,000 | - | - | Restricted Stock Units | |
| Daxor Corp. | Robert J. Michel | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Dec 2024 | 4,750 | 15,050 (0%) | 0% | 0 | Daxor Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 2,587 | 10,435 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2024 | 3,500 | 7,172 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2024 | 676 | 7,848 (0%) | 0% | 0 | Common Stock | |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 8,333 | 8,333 (0%) | 0% | 0 | Common Stock | |
| Geron Corp. | Michelle Robertson | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (Right to Buy) | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 1,429 | 3,672 (0%) | 0% | 0 | Common Stock | |
| Daxor Corp. | Robert J. Michel | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 8.70 per share. | 27 Mar 2024 | 750 | 11,300 (0%) | 0% | 8.7 | 6,525 | Daxor Common Stock |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 5,291 | 5,291 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michelle Robertson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 5,291 | 0 | - | - | Stock Option (right to buy) | |
| Geron Corp. | Robertson Michelle | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 850,000 | 850,000 | - | - | Employee Stock Option (Right to Buy) | |
| Daxor Corp. | Robert Michel J. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 06 Dec 2023 | 120 | 10,550 (0%) | 0% | 7.8 | 930 | Daxor Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2023 | 1,819 | 35,365 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 4,412 | 33,546 (0%) | 0% | 0 | Common Stock | |
| Daxor Corp. | Robert J. Michel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2023 | 14,000 | 14,000 | - | - | Stock Options (right to buy) | |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 4,348 | 29,134 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.87 per share. | 11 May 2023 | 949 | 106,610 (0%) | 0% | 9.9 | 9,369 | Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 1,429 | 24,786 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 3,847 | 23,357 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 94,500 | 94,500 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 31,500 | 107,743 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.89 per share. | 02 Mar 2023 | 184 | 107,559 (0%) | 0% | 8.9 | 1,636 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.67 per share. | 13 Feb 2023 | 4,287 | 76,243 (0%) | 0% | 9.7 | 41,435 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.16 per share. | 10 Jan 2023 | 1,752 | 80,530 (0%) | 0% | 8.2 | 14,296 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.23 per share. | 05 Dec 2022 | 193 | 82,282 (0%) | 0% | 10.2 | 1,974 | Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 2,098 | 18,810 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 700 | 19,510 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 06 Sep 2022 | 192 | 82,475 (0%) | 0% | 15.0 | 2,882 | Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2022 | 544 | 16,712 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 1,383 | 16,168 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 03 Jun 2022 | 1,527 | 82,667 (0%) | 0% | 11.5 | 17,617 | Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 474 | 14,785 (0%) | 0% | 0 | Common Stock | |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 1,539 | 14,311 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 414 | 12,772 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 5,000 | 12,358 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 1,738 | 7,358 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.33 per share. | 03 Mar 2022 | 767 | 84,194 (0%) | 0% | 17.3 | 13,290 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 11 Jan 2022 | 1,744 | 31,462 (0%) | 0% | 25.7 | 44,821 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 4,471 | 33,206 (0%) | 0% | 0 | Common Stock | |
| Verastem Inc | Michelle Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 63,493 | 63,493 | - | - | Stock Option (right to buy) | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 162 | 5,620 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 323 | 5,458 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 164 | 5,135 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2021 | 312 | 4,971 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.65 per share. | 09 Aug 2021 | 2,500 | 31,235 (0%) | 0% | 30.7 | 76,625 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 2,500 | 115,000 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 09 Aug 2021 | 2,500 | 28,735 (0%) | 0% | 60 | 150,000 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 2,500 | 117,500 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 28 Jun 2021 | 2,500 | 28,735 (0%) | 0% | 50 | 125,000 | Common Stock |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.65 per share. | 28 Jun 2021 | 2,500 | 31,235 (0%) | 0% | 30.7 | 76,625 | Common Stock |
| Daxor Corp. | Robert J. Michel | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 2,000 | 6,250 (0%) | 0% | 0 | Daxor Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 152 | 4,659 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 323 | 4,507 (0%) | 0% | 0 | Common Stock | |
| Daxor Corp. | Robert J. Michel | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 10.25 per share. | 19 Apr 2021 | 1,000 | 4,250 (0%) | 0% | 10.3 | 10,250 | Daxor Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 146 | 4,184 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 275 | 4,038 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 32,197 | 32,197 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 10,303 | 28,735 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Michelle Robertson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 78.27 per share. | 12 Jan 2021 | 1,568 | 18,432 (0%) | 0% | 78.3 | 122,727 | Common Stock |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2020 | 1,191 | 30,103 (0%) | 0% | 0 | Common Stock | |
| Bio-Key International Inc. | Robert J. Michel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 2,223 | 28,912 (0%) | 0% | 0 | Common Stock |